IMMUNOGEN INC Form SC 13G/A February 07, 2012

## **United States**

## SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## **SCHEDULE 13G**

**Under the Securities Exchange Act of 1934** 

(Amendment No. 2)\*

# IMMUNOGEN, INC.

(Name of Issuer)

**Common Stock** 

(Title of Class of Securities)

45253H101

(CUSIP Number)

#### December 31, 2011

(Date of Event Which Requires Filing This Statement)

Check the appropriate b	oox to designate the rule p	ursuant to which this Sche	dule is filed:
" Rule 13d-1(b)			

x Rule 13d-1(c)

" Rule 13d-1(d)

<sup>\*</sup> The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

#### CUSIP No. <u>45253H101</u>

(a) x

3. SEC Use Only

1. Names of Reporting Persons

(b) "

2. Check the Appropriate Box if a Member of a Group (See Instructions)

**BB Biotech AG** 

4. Citizen	ıship	or Place of Organization
Switz		and Sole Voting Power
Number of		
Shares	6.	O Shared Voting Power
Beneficially		
Owned by	7.	4,000,000 Sole Dispositive Power
Reporting		
Person with:	8.	0 Shared Dispositive Power
9. Aggreş	gate 1	4,000,000 Amount Beneficially Owned by Each Reporting Person
<b>4,000</b> 10. Check		e Aggregate Amount in Row (9) Excludes Certain Shares
[ ] 11. Percen	t of <b>(</b>	Class Represented by amount in Row (9)

#### 5.23%

12. Type of Reporting Person (See Instructions)

HC,CO

#### CUSIP No. 45253H101

1.	Names	of R	eporting	Persons
----	-------	------	----------	---------

#### Biotech Target N.V.

I.R.S. Identification Nos. of above persons (entities only):

#### N/A

- 2. Check the Appropriate Box if a Member of a Group (See Instructions)
  - (a) x (b) "
- 3. SEC Use Only
- 4. Citizenship or Place of Organization

#### **Netherlands Antilles**

5. Sole Voting Power

Number of

Λ

Shares

6. Shared Voting Power

Beneficially

Owned by

4,000,000

Each

7. Sole Dispositive Power

Reporting

Person

0

8. Shared Dispositive Power

with:

#### 4,000,000

9. Aggregate Amount Beneficially Owned by Each Reporting Person

#### 4,000,000

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares

[ ]
11. Percent of Class Represented by amount in Row (9)

5.23%

12. Type of Reporting Person (See Instructions)

 $\mathbf{CO}$ 

#### Item 4. Ownership

Provide the following information regarding the aggr	egate number and percentage	of the class of securities of the	e issuer identified in
tem 1.			

- (a) Amount beneficially owned: 4,000,000
- (b) Percent of class: 5.23%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote  $\underline{0}$
- (ii) Shared power to vote or to direct the vote 4.000,000
- (iii) Sole power to dispose or to direct the disposition of  $\underline{0}$
- (iv) Shared power to dispose or to direct the disposition of 4,000,000

#### Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURES**

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

#### **BB Biotech AG**

Date: January 31, 2012	By:	/s/ Michael Hutter Signatory Authority
	Name:	Michael Hutter
	Title:	Signatory Authority
Date: <u>January 31, 2012</u>	By:	/s/ Pascal Schmucki Signatory Authority
	Name:	Pascal Schmucki
	Title:	Signatory Authority
Biotech Target N.V.		
Date: <b>January 31, 2012</b>	By:	/s/ Michael Hutter Signatory Authority
	Name:	Michael Hutter
	Title:	Signatory Authority
Date: <u>January 31, 2012</u>	By:	/s/ Pascal Schmucki Signatory Authority
	Name:	Pascal Schmucki
	Title:	Signatory Authority

#### **Exhibit Index**

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.\*

\* Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V. s Schedule 13G filed with the Securities and Exchange Commission on May 14, 2010.